نتائج البحث - "Powderly, John D."

11

دورية أكاديمية

Differential drug responses of circulating tumor cells within patient blood

المؤلفون: Hughes, Andrew D., Marshall, Jocelyn R., Keller, Eric, Powderly, John D., Greene, Bryan T., King, Michael R.

المساهمون: National Institutes of Health, National Science Foundation Graduate Research Fellowship

المصدر: Cancer Letters ; volume 352, issue 1, page 28-35 ; ISSN 0304-3835

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.canlet.2013.08.026Test
https://api.elsevier.com/content/article/PII:S0304383513006010?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0304383513006010?httpAccept=text/plainTest

View record in BASE

12

دورية أكاديمية

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

المؤلفون: Goldman, Jonathan Wade, Piha-Paul, Sarina Anne, Curti, Brendan D., Pedersen, Katrina, Bauer, Todd Michael, Groenland, Stefanie L., Carvajal, Richard D., Chhaya, Vaishali, Hammond, Scott A., Streicher, Katie, Townsley, Danielle Michelle, Chae, Young Kwang, Voortman, Jens, Marabelle, Aurelien, Powderly, John D.

المصدر: Goldman , J W , Piha-Paul , S A , Curti , B D , Pedersen , K , Bauer , T M , Groenland , S L , Carvajal , R D , Chhaya , V , Hammond , S A , Streicher , K , Townsley , D M , Chae , Y K , Voortman , J , Marabelle , A & Powderly , J D 2020 , ' Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. ' , Journal of Clinical Oncology , vol. 38 , ....

العلاقة: https://research.vumc.nl/en/publications/f85ca7f8-e062-44c5-84af-a4a0ad4e1dcaTest

الإتاحة: https://research.vumc.nl/en/publications/f85ca7f8-e062-44c5-84af-a4a0ad4e1dcaTest

View record in BASE

13

دورية أكاديمية

Microtube Device for Selectin-Mediated Capture of Viable Circulating Tumor Cells from Blood

المؤلفون: Hughes, Andrew D, Mattison, Jeff, Western, Laura T, Powderly, John D, Greene, Bryan T, King, Michael R

المساهمون: National Science Foundation, NIH

المصدر: Clinical Chemistry ; volume 58, issue 5, page 846-853 ; ISSN 0009-9147 1530-8561

مصطلحات موضوعية: Biochemistry (medical), Clinical Biochemistry

الإتاحة: https://doi.org/10.1373/clinchem.2011.176669Test
http://academic.oup.com/clinchem/article-pdf/58/5/846/32658533/clinchem0846.pdfTest

View record in BASE

14

دورية أكاديمية

Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.

المؤلفون: Powderly, John D., Sullivan, Ryan J., Gutierrez, Martin, Khattak, Adnan, Thomas, Sajeve Samuel, Jimeno, Antonio, Pascarella, Stephanie, Zhu, Lili, Morrissey, Manju, Meehan, Robert S., Barlaskar, Ferdous, Brown, Michelle, Spigel, David R.

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS2676-TPS2676, 1p

15

دورية أكاديمية

Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.

المؤلفون: Davar, Diwakar, Knecht, John George, Vandross, Andrae Lavon, Perez, Cesar Augusto, Miller, David Michael, Powderly, John D., Bessudo, Alberto, Patel, Ekta, Fantini, Damiano, Paramasivan, Sattanathan, Crowe, David, Duncan, Meghan, Uptain, Susan, Luptakova, Katarina, Sullivan, Ryan J.

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe14685-e14685, 1p

16

دورية أكاديمية

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.

المؤلفون: Starodub, Alexander, Powderly, John D., Kim, Sung-Bae, Davar, Diwakar, Hill, Andrew Graham, Yeku, Oladapo O., Gabrail, Nashat Y., Krapp, Christian, Pihl, Susanne, Zhang, Ying, Slavsky, Sibel, Torrejon Castro, Davis Y, Uyei, Anne, Singel, Stina Mui, Kwatra, Vineet

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe14597-e14597, 1p

17

دورية أكاديمية

A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results.

المؤلفون: Frentzas, Sophia, Ahern, Elizabeth Stephanie, Weickhardt, Andrew James, Haydon, Andrew Mark, de Souza, Paul L., Powderly, John D., Wyant, Timothy, Tang, Jenny, Richards, Lori, Knickerbocker, Aron, Amit, Inbar, Ofran, Yanay, Vasselli, James Robert

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe14507-e14507, 1p

18

دورية أكاديمية

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

المؤلفون: Ulahannan, Susanna Varkey, Powderly, John D., Johnson, Melissa Lynne, Krauss, John C., Sharma, Manish, Davar, Diwakar, Karasic, Thomas Benjamin, Gaillard, Stephanie, Jenkins, Yonchu, Stagg, Robert J., Bomba, Darrin, Standifer, Nathan, Smith, Steven, Prasit, Peppi, Dubensky, Thomas Walter, Whiting, Sam H., Papadopoulos, Kyriakos P.

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p3107-3107, 1p

19

دورية أكاديمية

Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.

المؤلفون: Sharma, Manish, Kuboki, Yasutoshi, Camidge, D. Ross, Perets, Ruth, Sommerhalder, David, Yamamoto, Noboru, Bar, Jair, Parikh, Apurvasena, Li, Rui, Morrison Thiele, Gladys, Neagu Aristide, Martha Raluca, Freise, Kevin Jay, Powderly, John D.

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p3015-3015, 1p

20

دورية أكاديمية

A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.

المؤلفون: Hamid, Omid, Gutierrez, Martin, Mehmi, Inderjit, Dudzisz-Sledz, Monika, Hoyle, Paul Edward, Wei, Wendy, Powderly, John D.

المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p2599-2599, 1p

تنقيح النتائج